久久精品国产久精国产果冻传媒,黄色免费网站在线看,欧美中字慕日产2

Gene Editing Technology Innovation Platform

The Gene Editing Technology Innovation Platform (CRISTARS^®) is dedicated to developing international leading gene editing tools, obtaining core technologies with independent intellectual property rights, and paving the important foundation for gene editing technology translation. The platform is based on the combination of different single-stranded DNA deaminase structural domains and Cas9 nickase to develop a new generation of DNA base editing tools for broader and more accurate gene editing. The platform has successfully created the world-leading dual base editor and the ultra-high activity cytidine single-base editor (hyper CBE, HyCBE), which can efficiently convert two bases, improve editing activity and broaden the target range. The research results have been published in high-impact peer-review journals such as Nature Biotechnology, Nature Cell Biology, and Cell Research.

World's first successful application of CRISPR/Cas9 for mammalian gene editing

Gene editing is a technology to modify genes with precise modifications, which can be achieved with high efficiency and specificity for specific genomic DNA (or RNA), just as freely and accurately as editing text. In August 2013, a team of Bioraylab scientists published in the prestigious international journal Nature Biotechnology (IF≈43.11) the description of The CRISPR/Cas9 system was successfully used to edit genes in mice and rats. In the years since, Bioraylab scientists have continued to improve the gene editing system, applying it to a variety of applications including gene therapy, cell therapy and humanized animals.

The development of the era of gene therapy

In 2024, Science magazine announced CAR-T therapy for autoimmune diseases as “Breakthrough of the Year”.

In 2023, FUCASO, the world's first all human targeted BCMA CAR-T therapy (Equecabtagene Autoleucel) was approved for marketing by the Chinese NMPA for the treatment of recurrent or refractory multiple myeloma (R/R MM).

In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of R/R MM in China, was approved by the FDA for marketing.

In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry

In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia

In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA

In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)

In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (R/R ALL)

In 2016, the first generation of single-base editors were developed

In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced

In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)

In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced

In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)

In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced

In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)

About Us: About Us; Leadership; Our Culture; News; Join Us; Contact Us

Gene Therapy: Gene Editing Technology Innovation Platform; Hematopoietic Stem Cell Platform

Cell Therapy: Universal Cell Platform; Quickin CAR-T Platform; Enhanced T Cell Platform; In Vivo Gene Editing CAR-T Platform

Follow us on WeChat

Recruitment

Contact Us: Tel： 021-64340008; Email： info@brlmed.com; Address： Science&Technology Park, 3699 Yuanjiang Road, Minhang District, Shanghai

簡體中文

English

99偷拍视频精品一区二区_伊人久久无码精品亚洲日韩_884AA四虎影成人精品一区_校花被带到密室吸乳憋尿漫画_亚洲色图制服诱惑_美女视频黄a视频全免费观看_最新更新中文字幕91_日韓亞洲歐美在線觀看

Gene Editing Technology Innovation Platform

Gene Editing Technology Innovation Platform

World's first successful application of CRISPR/Cas9 for mammalian gene editing

The development of the era of gene therapy